Log in to your client extranet for free matter information, know-how and documents.
Mills & Reeve system for employees.
Our corporate team has advised AppCheck on securing a minority investment from LDC, part of Lloyds Banking Group, to support the cybersecurity software company's expansion and continued product development.
Our corporate team have advised on the sale of leading international fertility services provider, TFP Fertility, to a US private equity investor.
We've retained our Investors in People (IiP) platinum accreditation – a standard achieved by only 8% of assessed organisations.
We've advised the University of Sussex on its successful appeal against a record fine for breaching free speech.
We've strengthened our national commercial team with the appointment of senior industry specialist, Fiona Teague.
We're pleased to announce our sponsorship of the inaugural Ox Tech Week, taking place from 26 to 29 May, supporting a landmark event that will shine a spotlight on Oxford’s world leading innovation ecosystem.
We've become the first Midlands-based company to join the UK SCALE Centre’s flagship membership network, The Supply Chain Futures Forum.
Our team has advised the shareholders of Owen Mumford Holdings Limited on its agreement for the sale to embecta Corp. (Nasdaq: EMBC), a global leader in diabetes care technology, in a transaction valued at up to £150 million.
We've advised the University of Cambridge on a landmark strategic collaboration with IonQ, Inc., supporting the creation of the new IonQ Quantum Innovation Centre and long‑term research programme at the University’s Cavendish Laboratory.
We've bolstered our North West construction team with the appointment of four industry specialists.
We've strengthened our nationally recognised family team with the strategic lateral hires of two partners, Brett Frankle and Rachel Donald, who join our London office.
We've advised on an over-subscribed seed extension investment round for Microneedle Solutions (MNS), which will enable the company to advance its Miracus™ needle-free patch platform into first-in-human trials.